Atika Capital Management LLC Ultragenyx Pharmaceutical Inc. Transaction History

Atika Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$73.71 - $87.86 $2.93 Million - $3.49 Million	-39,700 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$77.92 - $102.4 $257,136 - $337,920	-3,300 Reduced 7.67%	39,700 $3.58 Million
Q2 2021 Aug 12, 2021	SELL	$92.19 - $115.71 $2.12 Million - $2.66 Million	-23,000 Reduced 34.85%	43,000 $4.1 Million
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $2.46 Million - $3.86 Million	-23,000 Reduced 25.84%	66,000 $7.52 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $877,760 - $1.84 Million	10,400 Added 13.23%	89,000 $12.3 Million
Q3 2020 Nov 13, 2020	SELL	$72.98 - $90.0 $29,192 - $36,000	-400 Reduced 0.51%	78,600 $6.46 Million
Q2 2020 Aug 13, 2020	BUY	$46.91 - $78.22 $1.9 Million - $3.17 Million	40,500 Added 105.19%	79,000 $6.18 Million
Q1 2020 May 14, 2020	BUY	$33.8 - $62.9 $1.12 Million - $2.08 Million	33,098 Added 612.7%	38,500 $1.71 Million
Q4 2019 Feb 14, 2020	BUY	$36.08 - $45.83 $194,904 - $247,573	5,402 New	5,402 $231,000
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $1.19 Million - $1.77 Million	-28,000 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$54.93 - $74.36 $1.54 Million - $2.08 Million	28,000 New	28,000 $1.78 Million

325

85.6M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.91B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.